Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Paxil NDA Covers Hemihydrate And Anhydrous Paroxetine, Company Says

Executive Summary

GlaxoSmithKline's Paxil NDA is not limited to the crystalline hemihydrate form of paroxetine marketed by the company, GSK maintained in a D.C. federal court filing.

You may also be interested in...



Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC

Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states

Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC

Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states

FTC Asks FDA To Clarify "Orange Book" Listing Criteria In Citizen Petition

Patents that claim any unapproved aspects of an approved drug should not be listed in the "Orange Book," the Federal Trade Commission maintained.

Related Content

UsernamePublicRestriction

Register

PS038072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel